Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R. Ogusu S, et al. Among authors: kudo k. Cancer Immunol Immunother. 2023 Nov;72(11):3765-3772. doi: 10.1007/s00262-023-03528-x. Epub 2023 Aug 28. Cancer Immunol Immunother. 2023. PMID: 37638979 Free PMC article.
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Uematsu S, et al. Among authors: kudo k. Thorac Cancer. 2023 Jan;14(2):168-176. doi: 10.1111/1759-7714.14729. Epub 2022 Nov 21. Thorac Cancer. 2023. PMID: 36408699 Free PMC article.
Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer.
Hasegawa T, Yanagitani N, Ohyanagi F, Kudo K, Horiike A, Tambo Y, Nishikawa S, Ariyasu R, Uchibori K, Kitazono S, Nishio M. Hasegawa T, et al. Among authors: kudo k. Int J Clin Oncol. 2021 Mar;26(3):507-514. doi: 10.1007/s10147-020-01822-7. Epub 2020 Nov 7. Int J Clin Oncol. 2021. PMID: 33159605 Clinical Trial.
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. Tanaka H, et al. Among authors: kudo k. Thorac Cancer. 2021 Jul;12(14):2113-2121. doi: 10.1111/1759-7714.14048. Epub 2021 Jun 2. Thorac Cancer. 2021. PMID: 34076966 Free PMC article. Clinical Trial.
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K. Sakai K, et al. Among authors: kudo k. Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1. Cancer Sci. 2013. PMID: 23721103 Free PMC article.
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
Okuma Y, Goto Y, Ohyanagi F, Sunami K, Nakahara Y, Kitazono S, Kudo K, Tambo Y, Kanda S, Yanagitani N, Horiike A, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Nishio M, Ohe Y, Hosomi Y. Okuma Y, et al. Among authors: kudo k. Cancer Med. 2020 Oct;9(20):7418-7427. doi: 10.1002/cam4.3385. Epub 2020 Aug 19. Cancer Med. 2020. PMID: 32813912 Free PMC article. Clinical Trial.
1,728 results